Enhancing erythropoietin therapy in ischaemia-reperfusion injury of heart and kidney

心脏病发作和因血流不足引起的肾脏疾病是发病率的常见原因，治疗方案很差。促红细胞生成素(EPO)是一种有用的新疗法，但对其在人类中的使用仍有一些警告：例如。它可能会在修复过程中造成过多的疤痕。促红细胞生成素与抗炎药物联合使用可能会减少疤痕，并对长期健康有利。我们计划仔细定义损伤和修复的生物分子途径，以更好地计划这种治疗方法供人类使用。

Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.